Direct myosin-2 inhibition enhances cerebral perfusion resulting in functional improvement after ischemic stroke by Pénzes, Máté et al.






2020; 10(12): 5341-5356. doi: 10.7150/thno.42077 
Research Paper 
Direct myosin-2 inhibition enhances cerebral perfusion 
resulting in functional improvement after ischemic 
stroke 
Máté Pénzes1#, Demeter Túrós1#, Domokos Máthé2, Krisztián Szigeti2, Nikolett Hegedűs2, Anna Ágnes 
Rauscher1, Péter Tóth3,4, Ivan Ivic3,4, Parasuraman Padmanabhan5, Gabriella Pál6,7, Árpád Dobolyi6, Máté 
Gyimesi1, András Málnási-Csizmadia1 
1. MTA-ELTE Motor Pharmacology Research Group, Eötvös Loránd University, Department of Biochemistry, Pázmány Péter sétány 1/c, 1117 Budapest, 
Hungary 
2. Department of Biophysics and Radiation Biology, Nanobiotechnology and In Vivo Imaging Centre, Semmelweis University, Tűzoltó utca 37-47, 1094 
Budapest, Hungary 
3. Department of Neurosurgery, University of Pécs, Medical School, Szigeti út 12, 7624 Pécs, Hungary 
4. MTA-PTE Clinical Neuroscience MR Research Group-Pécs Diagnostic Center, Pécs, Hungary 
5. Cognitive Neuroimaging Centre (CoNiC), Lee Kong Chian School of Medicine, 59, Nanyang Drive, Nanyang Technological University, Singapore-636921 
6. MTA-ELTE Laboratory of Molecular and Systems Neurobiology, Department of Physiology and Neurobiology, Eötvös Loránd University and the 
Hungarian Academy of Sciences, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary 
7. Hungarian Defense Forces Military Hospital, Róbert Károly körút 44, 1134 Budapest, Hungary 
#These authors contributed equally to this work  
 Corresponding author: András Málnási-Csizmadia, malna@elte.hu, ELTE Eötvös Loránd University, Department of Biochemistry, Pázmány Péter sétány 1/c, 
1117 Budapest, Hungary, Tel: +36-1-372-2500 ext. 8811, Fax: +36-1-381-2172 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2019.11.13; Accepted: 2020.02.03; Published: 2020.04.06 
Abstract 
Acute ischemic stroke treatment faces an unresolved obstacle as capillary reperfusion remains 
insufficient after thrombolysis and thrombectomy causing neuronal damage and poor prognosis. 
Hypoxia-induced capillary constriction is mediated by actomyosin contraction in precapillary 
smooth muscle cells (SMCs) therefore smooth muscle myosin-2 could be an ideal target with 
potentially high impact on reperfusion of capillaries.  
Methods: The myosin-2 inhibitor para-aminoblebbistatin (AmBleb) was tested on isolated human 
and rat arterioles to assess the effect of AmBleb on vasodilatation. Transient middle cerebral artery 
occlusion (MCAO) was performed on 38 male Wistar rats followed by local administration of 
AmBleb into the ischemic brain area. Development of brain edema and changes in cerebrovascular 
blood flow were assessed using MRI and SPECT. We also tested the neurological deficit scores and 
locomotor asymmetry of the animals for 3 weeks after the MCAO operation. 
Results: Our results demonstrate that AmBleb could achieve full relaxation of isolated cerebral 
arterioles. In living animals AmBleb recovered cerebral blood flow in 32 out of the 65 affected 
functional brain areas in MCAO operated rats, whereas only 8 out of the 67 affected areas were 
recovered in the control animals. Animals treated with AmBleb also showed significantly improved 
general and focal deficit scores in neurological functional tests and showed significantly ameliorated 
locomotor asymmetry. 
Conclusion: Direct inhibition of smooth muscle myosin by AmBleb in pre-capillary SMCs 
significantly contribute to the improvement of cerebral blood reperfusion and brain functions 
suggesting that smooth muscle myosin inhibition may have promising potential in stroke therapies as 
a follow-up treatment of physical or chemical removal of the occluding thrombus.  










Acute ischemic stroke is an ever-increasing 
disease affecting the entire world’s population despite 
the wide range of efforts to improve preventive 
strategies [1]. Ischemic stroke treatment with special 
focus on regeneration is of immediate and serious 
medical and economic interest due to the high 
occurrence of stroke and its serious lifelong 
consequences [2]. Stroke treatment with intra-arterial 
thrombolytics, such as plasminogen activators still 
remain the mainstay intervention per se or in 
combination with mechanical thrombectomy [3], 
which must be further evolved to decrease the 
mortality rate of the disease and to ameliorate the 
consequences for the stroke survivors [2]. These 
treatments should involve both acute and prolonged 
interventions including enhanced add-on therapies 
for mechanical thrombectomy. The major unresolved 
issue in stroke treatment is that cerebral capillaries 
remain closed by hypoxia-induced contraction of 
precapillary smooth muscle cells (SMCs) [4, 5] even 
after opening the large vessels by thrombectomy. The 
permanently constricted small vessels dramatically 
suppress tissue blood supply contributing to ultimate 
cell death in the penumbra. Therefore, a high unmet 
need is in the field for drug treatments enhancing 
restoration of local oxygen supply in the penumbra 
following hypoxia-induced ischemic cascade [6, 7]. 
Directly targeting the contractile apparatus of 
precapillary SMCs with a small molecule inhibitor 
may fulfill both short- and long-term requirements 
towards an innovative medication. In addition, a 
smooth muscle myosin (SMM) targeting treatment 
combined with thrombectomy and/or thrombolysis 
has the potential to extend the treatment-eligibility 
criteria thereby allowing effective therapies to a 
broader population of stroke patients. 
Restriction of blood supply during ischemic 
stroke was demonstrated to trigger the constriction of 
smooth muscle actin expressing contractile SMCs 
followed by SMC death in rigor [4, 5]. SMC 
contraction is most presumably due to complex 
cellular processes: a few minutes after ischemic stroke 
anoxic depolarization of cells induces the rise of 
intracellular Ca2+ release facilitating smooth muscle 
contraction. Moreover, hypoxia is followed by the 
decline in ATP levels, which hinders the detachment 
of myosin from actin thereby populating myosin in 
the strongly actin-bound, rigor state. In addition, the 
formation of oxygen and nitrogen radicals during 
ischemia also contributes to pericyte constriction [4, 8, 
9]. 
These events lead to the irreversible contraction 
of brain capillaries resulting in prolonged decrease in 
blood flow, downstream thrombus formation and the 
concomitant damages of neurons. 
The most promising advances in regeneration 
after stroke have been achieved by influencing the 
Rho-associated kinase (ROCK) pathway. ROCK is a 
central hub of several different pathways regulating 
protein synthesis, cell growth, cytoskeleton 
rearrangements and acto-myosin contraction in 
non-muscle cell cortices [10, 11]. Importantly, ROCK 
pathway is responsible for smooth muscle contraction 
in SMC-s through SMM activation thereby regulating 
blood pressure [12, 13]. Furthermore, intravenous 
administration of liposomal ROCK-inhibitor fasudil 
[14] was effective in recovery after stroke in rodent 
transient middle cerebral artery occlusion (MCAO) 
stroke models. However, the improvement of blood 
flow after ischemic stroke was not demonstrated in 
fasudil treated animals. 
We hypothesized that direct inhibition of SMM 
in pre-capillary SMCs might achieve the same 
positive effects as ROCK inhibition while avoiding the 
unwanted negative side effects of inhibiting an 
upstream hub regulator protein. In this study, we 
demonstrate that direct inhibition of SMM with a 
biologically safe blebbistatin derivative 
para-aminoblebbistatin (AmBleb) [15] restores 
cerebral blood perfusion and significantly improves 
neurological functions in MCAO operated rat stroke 
model. 
Materials and Methods 
Materials 
Chemicals were purchased from Sigma-Aldrich 
(Germany) if otherwise not stated. [99mTc]-HMPAO 
Brain-SPECT® kit was purchased from Medi- 
Radiopharma Co., Ltd. (Hungary). StemPro™ Neural 
Stem Cells and the required chemicals for cells were 
purchased from Thermo Fisher Scientific (USA). The 
isoflurane was purchased from Medicus Partner Ltd. 
(Hungary). 
Purification of actin and smooth muscle 
myosin 2 
Rabbit actin was prepared as described 
previously [16]. Smooth muscle myosin was prepared 
from chicken gizzard [17] and subfragment-1 (labeled 
as SMM in the manuscript for simplicity because we 
do not use other smooth muscle myosin forms) was 
prepared by activated papain digestion [18] (0.2 
mg/ml papain, 12 min, 25oC, reaction was stopped 
with 5 mM sodium iodoacetate). SMM concentration 
was determined with Bradford Protein Assay. 
ATPase activity measurements 
Steady-state ATPase measurements were carried 
out in 50 μl in a flat bottom 384-well plate 





(Nunc-Thermo Fischer) using NADH-PK/LDH 
coupled assay described previously [19] at 25oC in the 
presence of 0.5 mM ATP and F-actin (25 μM for NM2s 
and 33 μM for SmS1) in ATPase buffer (10 mM MOPS 
pH 7.0, 4 mM MgCl2, 2 mM β-mercaptoethanol) for 15 
minutes. Three parallel measurements were carried 
out for each point. Different concentration of AmBleb 
was added to the reaction in 0.5 μl DMSO (1% of total 
volume). DMSO and actin-controls were measured to 
each measurement set. ATPase activity was calculated 
from linear regression of the time dependent 
absorbance data collected at 340 nm. 
Vessel contraction assay - Vasomotor 
responses of rat and human cerebral 
parenchymal arterioles to AmBleb 
Following written informed consent and 
approved by the Regional Ethic and Review 
Committee of the University of Pécs (3887), we 
obtained cortical samples from patients undergoing 
neurosurgical removal of cerebral tumors without 
known comorbidities, which would have been 
discarded, as published previously [20]. In brief, 
preoperatively contrast enhanced magnetization 
prepared rapid acquisition gradient echo (MP-RAGE) 
MRI sequence was performed to visualize contrast 
enhancing areas with pathologically increased blood 
brain barrier permeability. Cerebral samples and/or 
the arterioles themselves were removed carefully 
from non-enhancing normal cortical areas that had to 
be removed to approach deep-seated tumors [20]. 
Cerebral tissue from the fronto-temporo-parietal lobes 
was placed in 0°C–4°C physiologic salt solution (PSS, 
110.0 NaCl, 5.0 KCl, 2.5 CaCl2, 1.0 MgSO4, 1.0 KH2PO4, 
5.5 glucose, and 24.0 mM NaHCO3 equilibrated with a 
gas mixture of 95% air and 5% CO2, pH ∼7.3). 
Afterward, intraparenchymal arterioles were isolated 
under an operating microscope, cut into rings and 
transferred into a wire myograph (Danish Myo 
Technology 610M, Aarhus, Denmark). Arterioles’ 
segments (1.5-2 mm in length) were suspended 
between two 40 µm tungsten wires in the myograph 
chambers containing constantly oxygenated PSS (36.9 
± 0.1°C). In separate series of experiments, approved 
by the Institutional Animal Use and Care Committee 
of the University of Pecs Medical School and the 
National Scientific Ethical Committee on Animal 
Experimentation, Hungary (BAI/35/51-107/2016) 
rats (n=6) were anesthetized, decapitated and basilar 
arteries (BA) were isolated and studied in the wire 
myograph. Before the start of an experiment, 
length-tension curve was obtained to determine the 
optimal passive tension for each vessel, then vessels 
were allowed to for one hour to equilibrate, according 
to the manufacturer’s instructions. Endothelial 
function was tested by relaxation responses to 
adenosine-triphosphate (ATP; from 10-9 to 10-4 M, 
Sigma Aldrich). Endothelium-independent relaxation 
was studied by administration of the NO donor 
sodium nitroprusside (from 10-9 to 10-4 M, Sigma 
Aldrich). Contractile ability of the vessels was tested 
by obtaining vasomotor responses to the 
beta-adrenergic agonist norepinephrine (from 10-9 to 
10-5 M, Sigma Aldrich). After the vessels reached 
maximal contraction (plateau phase) in response to 60 
mM KCl, vasomotor responses were assessed to 
cumulative concentrations of AmBleb (1, 10 and 30 
µM for 15 min each). After AmBleb treatment, 
vasoconstrictor and vasorelaxation functional 
reactivity were re-assessed. 
Animals 
Experiments were conducted on male Wistar 
rats (200-250 g body weight), bred in a Specific 
Pathogen Free unit at Toxi-Coop Ltd. (Budapest, 
Hungary). Animals were maintained in standard 
housing conditions with 12-hour light, 12-hour dark 
periods and were allowed free access to dry rat food 
and water. All procedures were conducted in 
accordance with the ARRIVE guidelines and the 
guidelines set by the European Communities Council 
Directive (86/609 EEC) and approved by the Animal 
Care and Use Committee of the Semmelweis 
University (protocol number: XIV-I-001/29-7/2012). 
Three animals were operated daily, animals were 
assigned to control or treated groups randomly.  
In vivo studies started only after we confirmed 
the effectiveness of AmBleb in numerous in vitro and 
cellular assays. We also aimed to first demonstrate the 
in vivo effectiveness of AmBleb on rodent animal 
models before recruiting larger animals, however, 
anatomical differences between the rodent and 
human brain vasculature may pose limitation to the 
translation of the applied methodology to human 
subjects. Furthermore, we made efforts to reduce the 
number of animals involved in the study by applying 
advanced biomedical imaging methods combined 
with the development of unbiased analysis methods. 
We kept animal numbers at a minimum level with 
which statistically significant results could be 
achieved.  
Middle Cerebral Artery Occlusion 
An intraluminal invasive endovascular surgical 
procedure, the Koizumi-type transient middle 
cerebral artery occlusion (MCAO) [21] was performed 
to model ischemic stroke by occluding the middle 
cerebral artery (MCA) in rats. Wistar rats and silicone 
filament coating were used to minimize mortality and 
variability [22]. Briefly, animals were pre-anesthetized 





with 4% isoflurane in medical oxygen in a closed 
plastic induction box. Once pre-anesthesia had taken 
place, the animal was transferred to the surgery table 
and fitted into a nose cone and isoflurane was 
reduced to 2% for maintenance. Firstly, a midline neck 
incision was carried out and the left common carotid 
artery (CCA), external carotid artery (ECA) and 
internal carotid artery (ICA) were exposed precisely 
and isolated from the surrounding tissues. After 
ligation of the CCA and ECA with silk suture (Silk 
suture USP 1, KRUUSE, Langeskov, Denmark), a 4-0 
silicone rubber-coated monofilament (4-0 Medium B 
MCAO suture L45 PK10, Doccol Corporation, Sharon, 
MA, USA) was inserted through the CCA into the ICA 
20 mm beyond the carotid bifurcation to occlude the 
MCA for 1 hour. 
Delivery of AmBleb into the brain 
The 1 hour-long MCAO was followed by the 
injection of either AmBleb (patent application 
number: EP16153446, 25 mM dissolved in DMSO) or 
vehicle into the left damaged hemisphere of the brain. 
Firstly, an anterior-posterior incision between the ears 
was carried out by a scalpel and kept open with 
surgery clamps. The surface of the skull was cleaned 
with H2O2 until the intersection between the coronal 
suture and sagittal sutures (bregma point) were 
visible. The injection coordinates were measured from 
the bregma using coordinates (AP +0.3 mm, ML -4.0 
mm, DV +4.8 mm) according to a rat brain atlas [23]. 
A 10 µl Hamilton syringe combined with 
microsyringe pump was used to deliver 0.5 μl 25 mM 
AmBleb or vehicle (DMSO) at a rate of 0.5 µl/min. 
This dose does not cause heart function deviations, 
because even 0.5 mg systematically introduced 
AmBleb (130-times higher than the amount injected 
here) does not affect heart functions (data not shown). 
Measurement of cardiovascular and 
respiratory functions 
Heart rate, pulse distention, breathe rate and 
blood oxygen saturation was measured by 
non-invasive MouseOx PlusR Pulse Oximeter for 
rodents (Starr Life Sciences Corp., PA, USA). 250 g 
Wistar rats were anesthetized with urethane and 
Pulse Oximeter Sensor was applied to the shaven 
neck. 0.5 mg AmBleb dissolved in 200 μl DMSO was 
injected intraperitoneally and vital functions were 
followed for more than an hour. 
TTC staining 
Prior to our experiments with AmBleb, we 
checked the reproducibility of the MCAO procedure 
on 6 animals and determined the extent and the 
localization of cerebral lesion 24 hours after MCAO. 
Briefly, we dissected the brain in the coronal plane at 
the bifurcation of MCA and anterior cerebral artery 
and visualized the cerebral lesion by TTC staining (0.1 
g 2,3,5-triphenyltetrazolium chloride dissolved in 5 
ml distilled water). 
Blood perfusion imaging measurements using 
Single Photon Computed Tomography 
(SPECT) coupled to neural tissue edema 
imaging with MRI 
Cerebral blood perfusion was measured using 
the validated and high-sensitivity method of single 
photon emission computed tomography (SPECT). 
Brain tissue water content changes and related 
morphological alterations were regionally assessed by 
magnetic resonance imaging (MRI) coupled to SPECT. 
SPECT/MRI images were obtained in each animal at 3 
hours, and at 3, 7, 10, 14, 17 and 21 days after the 
MCAO stroke model induction. 
SPECT and MRI were carried out on rats 
anesthetized with 2% isoflurane in medical oxygen 
immobilized and fixed in a specifically designed 
animal anesthesia, restraining and heating bed 
(Multicell, Mediso Ltd., Hungary). For SPECT 
detection of blood perfusion changes, 80-160 MBq 
[99mTc]-HMPAO (Brain-SPECT® kit, 
Medi-Radiopharma Co Ltd., Hungary) was 
administered to the animals 60 minutes prior start of 
SPECT imaging, via tail vein bolus injection in 300-600 
µl volumes. The applied radiopharmaceutical, 
99mTc-[d,l]-hydroxy-methylene-paraamino-oxime 
([99mTc]-HMPAO) accumulates in brain tissue (glia, 
neurons, microglia, and nonneural cells like choroid 
plexus) as a function of the tissue blood perfusion in 
the CNS. After delivery by capillaries, the radiotracer 
is entrapped inside the cells behind the blood-brain 
barrier (BBB) and its quantifiable radioactivity is 
proportional to the initial perfusion of the given brain 
region. 
The SPECT measurements were performed on a 
NanoSPECT/CT+ (Mediso Ltd, Hungary) imaging 
system. A helical data acquisition was performed in 
50 minutes on each animal with 100 frames and 120 
seconds per frame in a 256x256 column/row matrix 
with 125x125 μm/pixel resolution. Collected data 
were reconstructed using the Mediso Tera-TomoTM 
Monte-Carlo model-based maximum likelihood 
expectation maximization (MLEM) SPECT 
reconstruction algorithm running on the Nucline 
(Mediso Ltd., Hungary) software. Brain volumetric 
radioactivity data in 330 µm isovoxels were obtained 
and quantified in units of radioactivity measured in 
MBq/ml.  
MRI acquisitions were performed immediately 
following the [99mTc]-HMPAO injection, using a 
nanoScan® 1T MRI system (Mediso Ltd, Budapest, 





Hungary) with a dedicated transmit/receive rat coil. 
A T2 weighted Fast Spin Echo (FSE) 
three-dimensional sequence had 460 µm in-plane 
resolution, slice thickness: 460 µm, repetition and echo 
times 2000 ms and 78.9 ms, 80 frequency- and 64 
phase encodings, 90 degrees flip angle and 2 
excitations resulting in a 25 minutes 44 seconds 
acquisition. Image analysis of 3D SPECT and MRI 
VOIs was performed with VivoQuant software 
(InviCRO, Boston, MA). MRI images were employed 
as reference to the SPECT of the same animal in each 
imaging time point. During analysis, each animal’s 
SPECT/MRI co-registered image was also 
co-registered to a MRI brain atlas template using the 
co-registration tool in SPM12 (7219).  
Quantitative Image Analysis Signal removal 
from extrameningeal tissue 
Firstly, to quantify the MRI and SPECT 
recordings, the extrameningeal tissues were 
discarded. Using BrainSuite18a (developed by David 
Shattuck et al. at UCLA) the skull tissues were 
removed from the MRI volumes using the 
skull-stripping pipeline with additional manual 
alignments in each slice. The final brain masks were 
applied to the previously co-registered SPECT 
volumes as well.  
Reconstruction of cerebral edema from MRI 
images 
For the quantification of the cerebral edema 
volume on the MRI dataset, the pixel intensity 
histograms of the hemispheres were determined 
using the stack histogram tool in Fiji [24]. For 
determining the pixel intensity threshold for edema, 
Gaussian curves were fitted onto the histogram values 
of the contralesional (right) hemispheres and from the 
mean of the Gaussian curve; two times the standard 
deviation was subtracted. This threshold was set as 
the absolute intensity threshold for the surface tool in 
the 3D bioimaging and reconstruction software Imaris 
v 9.0.2. (Bitplane Inc.), to reconstruct the cerebral 
edema volume. In the contralesional hemisphere, this 
threshold value excluded 97.6% of all pixels; the 
remaining 2.4% with the highest pixel intensity 
correspond to the brain ventricles. The volume of the 
contralesional ventricles was subtracted from the 
cerebral edema volume, since the isolation of the 
ventricles on the edema-affected hemisphere was not 
possible in most cases. To remove the 
space-occupying effects of vasogenic edema, we 
performed a correction method by calculating the 
differences between the ipsi- and the contralesional 
hemispheres and removing the excess area from the 
edema volumes to get the final infarction size [25]. For 
the statistical comparison of edema volumes unpaired 
t-test was applied. 
SPECT parametrization and segmentation  
A parametric map was created from our masked 
SPECT recordings and the SPECT 99mTc-HMPAO 
dataset of healthy rats [26, 27] by transforming the 
SPECT signals to relative rCBF values. In the absence 
of arterial input function relative rCBF values were 
used in all analysis, for simplicity throughout the text 
we refer to relative rCBF as rCBF. For the parametric 
maps each voxel was transformed sequentially by 
applying the Lassen’s correction algorithm [28] (α = 
0.5), selecting the right hemispheres as reference 
regions. The parametric maps were co-registered with 
a rat brain atlas [29] and segmented into 72 functional 
regions described in the atlas (from the 77 regions 
described in the atlas, regions 4, 13 and 75 did not 
contain measurement data, regions 56 and 71 
contained incomplete data, therefore these were 
excluded from analysis). The relative rCBF values 
were determined by averaging the voxel values in 
ROIs of the co-registered parametric map.  
The rCBF (regional cerebral blood flow) 
analysis 
The co-registered parametric maps were 
imported to MATLAB R2018b for further analysis:  
1. The mean ± SD values of the physiologically 
normal relative rCBF for each functional brain region 
were calculated from the dataset of healthy rats. The 
hypo- and hyperperfused voxels of MCAO treated 
rats were selected by setting up a threshold for both 
by subtracting/adding 2xSD to the mean rCBF values 
of the reference dataset, corresponding to the 95% 
confidence interval in each individual brain region. 
Hypo- and hyperperfused brain volumes were 
constructed by grouping voxels outside these 
thresholds. 2. We evaluated the relative rCBF changes 
over time by using the day 0 hypoperfused volume as 
a 3D mask. The mask was applied to all 
measurements in the time-series of the same animal 
and either the voxels contained in these ROIs of the 
parametric maps were averaged for each time point 
(voxel-wise), or the SPECT signals were averaged and 
then transformed using Lassen’s algorithm (roi wise). 
3. The relative rCBF calculation for the functional 
regions present in the rat brain atlas was performed 
for each measurement point by averaging the voxel 
values corresponding to each region. By relating the 
values to those of the reference dataset, we obtained 
discrete relative rCBF values for every functional 
region. We classified brain regions into two groups 
based on whether the rCBF value was significantly 





different (non-regenerated) from the reference regions 
or not (regenerated). 
Neurological Scoring Tests 
To avoid abusing the animals with imaging 
procedures and neurological test assessments on the 
same day, neurological scoring tests were carried out 
1 day after the imaging days except for day 21. The 
neurological status of the animals was assessed on 
days 4, 8, 11, 15, 18 and 21 after MCAO by scoring 
tests relating to focal and general deficits [30]. Slight 
modifications in the scoring system were 
implemented as neither epileptic nor circling behavior 
were present in the animals and climbing was not 
tested, consequently these three scores were omitted 
from analysis. The observer who scored the animals 
was blinded to the identity of the individual animals. 
In case of general deficits animals were scored 
between 0-4 or 0-2 based on the severity as follows: 
posture (0: normal, 1: hunched, unstable, 2: upright 
head and/or body rest on ground, 3: lies on side, can 
assume prone position with strain, 4: passive, lies as 
placed), spontaneous activity (0: normal, 1: calm, 
quiet, explores slowly, 2: inert, somnolent, not 
exploring, 3: lethargic, stuporous, some movements in 
place, 4: no spontaneous movements), hair (0: normal, 
1: localized disorder, especially around eyes and nose, 
2: generalized disorder, ruffled and/or dirty fur) and 
eyes (0: normal, 1: rheumy, 2: dark discharge, 3: 
semi-closed, 4: closed). Since the condition of eyes was 
almost completely recovered at day 8 in both control 
and treated groups therefore it was excluded from the 
cumulative analysis of general deficit scoring. 
In case of focal deficits animals were scored 
between 0-4 based on the symptoms as follows: body 
symmetry (0: normal, 1: slight asymmetry, 2: 
moderate asymmetry, 3: prominent asymmetry, 4: 
extreme asymmetry), gait (0: normal, 1: stiff, 
inflexible, 2: limping, 3: trembling, drifting, falling, 4: 
does not walk), front limb symmetry (0: normal, 1: 
light asymmetry, 2: marked asymmetry, 3: prominent 
asymmetry, 4: slight asymmetry, no body/limb 
movement), compulsory circling (0: not present, 1: 
tendency to turn to one side, 2: circles to one side, 3: 
pivots to one side sluggishly, 4: does not advance) and 
Whisker-response (0: symmetrical response, 1: light 
asymmetry, 2: prominent asymmetry, 3: absent 
response ipsilesionally, diminished contralesionally, 
4: absent proprioceptive response bilaterally). For 
analysis, average scores ± SEM were calculated at 
each time point for the control and treated groups, 
significance of difference was evaluated by unpaired 
t-test. 
Cylinder test 
To evaluate locomotor asymmetry, MCAO 
treated rats were tested in an open-top, 21 cm 
diameter, clear glass cylinder 4, 8, 11, 15, 18 and 21 
days after MCAO operation and AmBleb treatment. 
Forelimb activity was calculated from number of 
touches of each forelimb against the wall of the arena. 
Forelimb use was defined as the whole palm touched 
the sidewall of the cylinder. Number of sidewall 
touches was counted for 2 minutes. 
Statistics 
The number of replicates (n) is indicated in the 
figure legends and refers to the number of 
experimental subjects independently treated in each 
experimental condition. Data are presented as means 
± SEM. Statistical analysis was carried out using 
unpaired two sample t-test in GraphPad Prism 7 and 
normality was tested using the Shapiro-Wilk test 
unless otherwise stated. Statistical significance was set 
at *p < 0.5, **p < 0.01. 
Results 
AmBleb, a potent inhibitor of SMM, relaxes 
contracted human arterioles 
Blebbistatin has been previously reported to be 
an inhibitor of SMM and arterial contractions [31]. As 
vasodilatation through SMC relaxation could be an 
important effect in stroke therapies (Figure 1A), we 
assessed that AmBleb retained the inhibitory effects 
on SMM described for blebbistatin [32, 33] (Figure 1B). 
The major advantages of AmBleb are its improved 
solubility, chemical stability and non-cytotoxicity in 
contrast to blebbistatin [15]. Therefore, AmBleb can be 
safely applied in vivo. We measured the vasodilatation 
effect of AmBleb on isolated rat and human arterioles 
(Figure 1C-E, Figure S1). Contracted arterioles were 
treated with increasing amounts of AmBleb and full 
dilatation of the arterioles was achieved at 30 μM 
AmBleb concentration with human arterioles being 
more responsive to AmBleb treatment than rat vessels 
(Figure 1D-E). Importantly, the upstream regulator of 
vasoconstriction, norepinephrine, did not cause vessel 
constriction in the AmBleb-dilated arterioles 
demonstrating that direct myosin inhibition 
overcomes signaling from upstream regulators 
(Figure 1E). These in vitro results encouraged us to 
investigate the effects of AmBleb in in vivo rodent 
stroke models.  
Substantial improvement in post-stroke 
cerebral blood flow by AmBleb treatment 
As a proof-of-concept for the positive effects of 
direct myosin-2 inhibition on recovery after stroke, 





MCAO was applied to model acute ischemic stroke on 
34 male Wistar rats. To maximize reproducibility we 
did not include females, as sex may influence the 
response to neuroprotective agents [34]. A single 
injection of AmBleb or DMSO vehicle was 
administered directly into the ischemic region with 
stereotaxic targeting immediately after the removal of 
the occluding filament to mimic the effect of a 
potential stroke treatment following thrombectomy 
(Figure 2A-B). Three animals died within 72 hours, 
the remaining 31 were monitored for 21 days. We 
investigated the development of brain edema and 
cerebrovascular blood flow by MRI and SPECT, 
respectively, on 6 control and 6 AmBleb treated 
animals for 3 weeks after the MCAO operation. 
We also investigated the effect of AmBleb 
treatment on cardiovascular and respiratory functions 
(Figure S2). We administered intraperitoneally 
125-times higher dose (0.5 mg) AmBleb to the same 
size Wistar rats than those underwent MCAO 
operation and AmBleb treatment (4 μg). Importantly, 
we did not see any significant change on heart rate, 
blood flow through the carotid arteries, breath rate 
and oxygen saturation, suggesting that even if 
AmBleb is not selective for SMM, it does not influence 
vital functions in the applied concentration range. 
Brain tissue edema was identified on the 
skull-stripped MRI images based on the intensity 
histograms of the two hemispheres. In agreement 
with other studies [35-37], we observed brain tissue 
 
 
Figure 1. Direct smooth muscle myosin inhibition relaxes contracted cerebral arterioles. (A) Schematic figure of inhibition of SMM in pre-capillary smooth muscle 
cell by AmBleb during stroke. (B) ATPase activity of human SMM is efficiently inhibited by blebbistatin and AmBleb (IC50bleb,SMM = 3 µM and IC50AmBleb, SMM = 12 µM). (C) AmBleb 
induced vasodilatation can restore capillary blood flow by relaxing smooth muscle myosin in SMCs as demonstrated on isolated human and rat arterioles. Addition of 1, 10 and 
30 μM AmBleb is labeled with light gray, gray and black arrowheads, respectively, series of NE addition (0.01-10 μM) is labeled with purple arrowheads. (D) Human arterioles 
were more sensitive for AmBleb than rat vessels indicated by the faster relaxation rate and the lower ED50 values for human arterioles (ED50,human< 1 μM, ED50,rat= 10 μM), while 
DMSO alone had no effect on vasodilation. (E) The AmBleb-dilated vessels in both human and rat arterioles were unresponsive to norepinephrine (NE), an upstream regulator 
of vasoconstriction. 
 





edema development 3 days after MCAO (Figure 2C), 
which remained consistent during the 21 days of 
investigation both in the control and in the AmBleb 
treated animals (Figure 2D). The lack of decrease in 
brain edema size during a 3-week follow-up period is 
also in line with recent findings by other groups 
[38-46], and due to its different molecular targets 
AmBleb is not expected to play a role edema 
development [47]. Nonetheless, a drastic increase in 
cerebral blood flow was detected by SPECT in the 
AmBleb treated animals compared to the control 
group (Figure 2E). Relative regional cerebral blood 
flow (rCBF) was determined from SPECT records by 
the Lassen’s correction algorithm [28, 48] and the 
rCBF was compared to those of 15 healthy Wistar 
male rats [26, 27] (Figure S3A).  
We followed the change of the total 
hypoperfused volume in the treated and untreated 
animals. After 3 days of MCAO, a striking difference 
was observed between the control and the AmBleb 
treated animals and the difference remained 
significant for another 11 days (Figure 2F). A slight 
but statistically not significant relapse of the 
hypoperfused volume was detected after day 14 in the 
AmBleb treated group. 
We also determined the changes in rCBF values 
in the initially hypoperfused region for 21 days 
(Figure 2G). By day 7, rCBF values in the stroke 
affected hypoperfused region were 41% higher in the 
AmBleb treated animals than those of the control rats. 
This difference in blood flow remained significant for 
1 week and then a slight relapse was observed. We 
note that the rCBF averaging based on ROI and voxels 
gave similar results (Figure 2G). 
From the total number of voxels that are 
significantly different from the healthy counterparts 
we could define the stroke-affected brain volume as a 
function of distance from the injection site (Figure 
2H). These values were calculated for both the control 
and the AmBleb treated animals from which we could 
determine brain volumes that were recovered by 
AmBleb treatment over the control recovery level 
(Figure 2I). This analysis shows the core region, which 
is prone to cell death (0-1 mm) could not be recovered 
effectively by AmBleb. However, the penumbra 
region (2-6 mm from the injection site) improved 
drastically better than in the control group. 
By day 7 in the ipsilesional hemisphere the 
hypoperfused volume shrank by 67% in the treated, 
while only 1% in the untreated animals. In the 
contralesional hemisphere the volume of the hypo- 
and hyperperfused areas did not change significantly 
in the treated and the untreated animals indicating 
direct local effect of AmBleb (Figure 3, Table S1).  
Cerebral blood flow of 32 out of 65 affected 
brain regions in the AmBleb treated animals 
was restored to healthy levels  
In healthy animals there are both characteristic 
differences in rCBF levels between the functional 
regions within a hemisphere, and also region-specific 
differences between the two hemispheres (Figure 4A, 
Figure S3). To identify functional brain regions that 
are affected by stroke and those brain regions that are 
prone to regeneration, the rCBF values of 72 
functional brain regions were compared [29] (Table 
S1) in both hemispheres of the control and AmBleb 
treated animals to those 15 healthy Wistar male rats 
[26, 27] (Figure 4A, Figure S3). On Day 0 (3 hours after 
MCAO) the rCBF values of control and treated groups 
showed no difference; rCBF values in the ipsilesional 
hemisphere and the contralesional cortex regions 
were generally lower, while rCBF values in the 
contralesional subcortical regions were slightly higher 
compared to the healthy levels. Although the rCBF 
values had a tendency to approach healthy levels 
during the first week in both groups, recovery in the 
ipsilesional hemisphere was enhanced by AmBleb 
treatment (Figure 4B). On day 0, MCAO affected the 
rCBF of 65 and 67 regions in the control and treated 
animals, respectively. (Figure 4B, Figure S3-5, Table 
S2). On day 7, 32 out of the 65 affected areas recovered 
in the treated animals while only 8 out of the 67 
affected regions showed improvement in control 
animals. (Figure 4C, Figure S3-5, Table S2). 5 of these 
regions improved both in the control and treated 
animals while 27 functional regions recovered only in 
the AmBleb treated animals (Figure 4C). 3 recovered 
hypoperfused regions in the treated animals became 
slightly hyperperfused (regions 33, 36 and 61), while 
none of them became hyperperfused in the control 
group. AmBleb treatment significantly enhanced the 
recovery as the rCBF of 32 regions including the most 
important functional regions were recovered (Figure 
4D, Figure S4). By contrast, these regions had 
significantly reduced rCBF values in the control 
animals. We note that the rCBF values of some 
important regions responsible for controlling motor 
functions did not recover to the normal range, 
however, their rCBF values showed marked 
improvements between day 0 and day 7 in treated 
animals (Figure 4D). We also note that the functional 
regions closer to the injection site had a higher 
tendency for improvement than those farther away 
from the injection site (Figure 4C), also indicating the 
direct, local effects of AmBleb in the recovery of 
stroke-related ischemic brain area.  






Figure 2. Cerebral blood flow at the ischemic brain region recovers 7 days after MCAO while brain edema remains constant during the 3 weeks of 
investigation. (A) Experimental timeline. (B) TTC staining of a representative brain slice shows a well-defined ischemic region as a result of MCAO. The injection site is marked 
on the overlaid rat brain atlas. (C) Representative MRI slices of brain edema development of control and AmBleb treated animals’ brains obtained 3 hours (day 0) and 7 days after 
MCAO. (D) Quantitative MRI analysis of brain edema development of control and AmBleb treated animals’ brains up to 21 days after MCAO. (E) 3D reconstruction of rCBF 
values in the ischemic area. Dotted line on the 3D reconstruction images marks the hypoperfused volume at day 0 and day 7. (F) Hypoperfused volumes at each time point up 
to 21 days. In the relative hypoperfused volumes significant changes can already be observed between the treated and control animals from day 3. (G) rCBF values in the volume 
defined as hypoperfused at day 0 on the ipsilesional hemisphere both voxel-wise (dark blue/grey) and roi-wise (light blue/grey). (H) Volume of brain tissue significantly different 
from the healthy level is shown as a function of distance from AmBleb injection site on day 3 (purple) and day 7 (orange). Total brain volume is also shown (gray) for comparison. 
(I) Difference of healthy brain tissue volumes between treated and control brains is shown as a function of distance from AmBleb injection site on day 3 (purple) and day 7 
(orange). Note that AmBleb effect is the most pronounced in the penumbra region (2-6 mm from the injection site), which has high importance in stroke interventions. Data 
represent the mean ± SEM (n=6 per group), p values were determined by unpaired t-test. *p < 0.05, **p < 0.01, scale bars: 2.5 mm. 






Figure 3. Hypoperfused brain areas are significantly reduced in the ipsilesional hemisphere upon AmBleb treatment. (A) Extended brain slices: (15 mm) 
showing hypo- (cyan or pink) and hyperperfused (green or red) areas co-registered with MRI in control or treated groups, respectively. Images were created by averaging the 
parametric maps containing only the hypo- and hyperperfused voxels. On day 0 control and treated groups were identically affected by MCAO indicated by the substantial overlap 
of hypo- and hyperperfused areas on the merged images on the right panels (cf. Table S1). By day 7 on the ipsilesional hemisphere in the treated group greater volume was 
hyperperfused and less was hypoperfused compared to the control group. Scale bar: 2.5 mm. (B) Graphical representation of the fraction of healthy (orange), hypo- (cyan in 
control, pink in treated animals) and hyperperfused (green in control, red in treated animals) brain regions at day 0 and day 7 in the ipsilesional (upper four pie charts) and 
contralesional (lower four pie charts) hemispheres. All data points in this figure are from Table S1. (n=6 for each group). (C) On day 7 the affected volume in control (gray bars) 
and treated (blue bars) animals decreased markedly. At the ipsilesional side 46.7% of originally affected areas recovered in the treated animals while only 8% of the affected areas 
improved in control rats. Blood flow changed identically on the contralesional hemispheres of control and treated animals. 
 
Neurological deficits significantly improved in 
AmBleb treated rats 
After MCAO the general and focal neurological 
deficits were followed on 16 control and 15 AmBleb 
treated animals including the ones tested in 
MRI/SPECT imaging (Figure 5A-K). Locomotor 
asymmetry was assessed in a cylinder test on 4-4 
animals and significant improvement was observed 
on days 8-11 (Figure 5L). General deficit scoring was 
performed on body posture, spontaneous activity, 
hair ruffle and eye conditions (Figure 5C). Since eye 
condition recovered almost completely by day 8 in 
both groups, these scores were not cumulated with 
the other three parameters. These three deficits 
improved substantially in the treated animals by day 
8. The difference of the general deficits cumulative 
scores remained significant between the treated and 
control groups for 18 days (Figure 5A). 






Figure 4. Cerebral blood flow in 32 out of 65 affected brain regions significantly improved in the ipsilesional hemisphere 7 days after stroke. (A) Healthy 
(orange), control (gray) and treated (dark blue) rCBF levels in 72 functional regions (50 cortical and 22 subcortical) of both hemispheres on day 0, 3 and 7 after MCAO. On the 
ipsilesional hemisphere, treated and control rCBF values overlap almost entirely on day 0. However, on day 7 the control and the AmBleb treated regions strikingly differ. 
Difference between control and AmBleb treated rCBF in the contralesional hemisphere stays very low (c.f. Figure S1). (B) rCBF values of 72 functional regions in the ipsilesional 
hemisphere of the brain in the control (left panels) and AmBleb treated group (right panels) compared to the reference healthy rCBF level. Color-coding reflects the rCBF values 
relative to the rCBF of the respective region in healthy animals (c.f. Figure S1B). Orange (healthy rCBF value) represents that the rCBF is identical to that of the healthy animals. 
Note that cerebellum was excluded from the analysis. (C) Color-coding reflects rCBF improvement from day 0 to day 7 in each functional region of the ipsilesional hemisphere. 
Gray regions recovered only in the control or were unaffected by MCAO. AmBleb treatment resulted in full recovery (green) or hyperperfusion after recovery (blue). Yellow 
regions improved in both the control and treated groups. Red regions did not recover in any group. (D) Time dependent changes in rCBF values of key functional regions 
(striatum - 60, internal capsule - 62, primary somatosensory cortex barrel field - 31, secondary somatosensory cortex - 40, pallidum - 64, corpus callosum - 67, primary motor 
cortex - 19, secondary motor cortex - 20, olfactory structures - 72, optic pathways - 76). Each panel represents the rCBF values of the ipsilesional (left, darker symbols) and 
contralesional (right, lighter symbols) hemispheres of the control (gray) and the AmBleb treated (blue) animals with reference to the physiologically normal rCBF levels of healthy 
animals (orange bands) in the indicated brain regions. Data represent the mean ± SEM (n=15 AmBleb treated, n=16 control) *p < 0.05. NS marks motor cortex regions where 
rCBF values remain significantly below the healthy range on day 7, however, still show marked improvements between day 0 and day 7. Data represent mean ± SEM (n=6 
control/AmBleb or 15 healthy). 






Figure 5. – Neurological deficits improve significantly faster in AmBleb treated animals compared to the control group. Cumulative analysis of general (A) and 
focal (B) deficit scores indicates significant difference between control and treated animals during the test period. Average scores of individual symptoms illustrate the details 
underlying the improvement in the neurological status (C-K). Cylinder test was conducted to investigate the locomotor assessment and significant improvement was observed 
between day 8 and day 11 (L). Data represent the mean ± SEM (n=15 AmBleb treated, n=16 control) *p < 0.05, **p < 0.01. 
 
 
We further analyzed focal deficits of the animals 
in body symmetry, gait, front limb symmetry, 
compulsory circling and Whisker response (Figure 
5B). Cumulative focal deficit scores were significantly 
lower in treated animals than in control ones from day 
8 throughout the entire test period except for the last 
day (Figure 5B). Interestingly, except for body posture 
and Whisker response, we did not observe the relapse 
in general and focal neurological test features that we 
observed in blood flow analysis (cf. Figure 2), 
indicating that AmBleb treatment might have 
different dynamic effects on vascular and 
neurological functions. 
Discussion 
We demonstrated that AmBleb has drastic effect 
on vasodilation of both rat and human arterioles due 
to the effective relaxation of SMM in the same 
concentration range as the inhibitory constant for 
myosin-2 ATPase activities. We propose that the 
effective vasodilatator effect is realized in the in vivo 
experiments, and AmBleb treatment significantly 
enhanced the rCBF and accelerated neurological 
improvements after MCAO in the 3-week follow-up 
period. The observed changes in rCBF values and 
neurological scores of the control group are in line 
with previous studies [49, 50] confirming the 
reliability of our tests. 
Although AmBleb is not myosin-2 isoform 
specific, the locally applied effective dose is more than 
100-times less than the dose administered 
systematically with no effect on cardiovascular and 
respiratory functions (Figure S2), suggesting that 
effective treatment can be achieved with no effect on 
vital functions. 






Figure 6. – Regulation of smooth muscle myosin activity in the precapillary smooth muscle cells. SMM is the final effector of small vessel constriction. Actomyosin 
contraction is regulated through dynamic phosphorylation pattern of myosin light-chains mediated by myosin light-chain kinases (MLCK) and phosphatases (MLCP). Both MLCK 
and MLCP are under the complex control of several upstream regulators (e.g. Rho-associated kinase (ROCK) and norepinephrine (NE)). However, ROCK is a central hub 
protein, which modulates essential cellular processes such as protein synthesis, cell growth and cytoskeleton regulation, thus, ROCK inhibition to achieve SMC relaxation would 
lead to wide range of side effects. By contrast, direct inhibition of myosin by AmBleb (yellow triangles) can relax SMC contraction independently from upstream signaling pathways 
as we demonstrated in Figure 1 that AmBleb induced actomyosin relaxation could not be overcome by vasoconstriction signaling from NE pathway. 
 
Our advance in improving recovery after stroke 
by direct SMM inhibition provides a new concept that 
earlier successes in MCAO post-stroke regeneration 
with ROCK pathway inhibitors [14, 51-59] may, at 
least partly, also involve SMM as main downstream 
effector (Figure 6). The ROCK inhibition mediated 
SMM inhibition, and the corresponding opening of 
capillaries might have been a major effect of liposomal 
fasudil treatment [14]. However, inhibition of 
regulatory hub proteins upstream of myosin may also 
have negative effects on stroke regeneration by 
inducing large scale actin depolymerization [11] and 
inducing apoptotic pathways [60]. Hence direct 
inhibition of SMM could be of substantial value to 
achieve the same positive effects as ROCK inhibition 
while avoiding the unwanted negative side effects. 
The importance of direct inhibition of SMM is even 
highlighted that the upstream regulator 
norepinephrine did not induce vessel constriction in 
the AmBleb-dilated arterioles (Figure 1C, 1E, Figure 
6).  
Direct myosin-2 inhibition could also affect other 
substantial processes during stroke regeneration, 
which might also contribute to improved rCBF values 
after AmBleb treatment. It was demonstrated that 
myosin-2 inhibition promotes angiogenic sprouting 
and initial vascular branching [61]. The Rho/ROCK 
signaling pathway, which is the upstream regulator of 
SMM activity, has also been identified as an important 
regulator of endothelial permeability, and 
consequently direct myosin-2 inhibition has been 
supposed to play an important role in maintaining 
endothelial integrity and vascular permeability [62, 
63]. Furthermore, blebbistatin was shown to decrease 
the contractile force of platelets which has an 
important role to hold the integrity of homeostatic clot 
[64], suggesting that myosin-2 inhibition can also help 
to remove the blood clots formed during ischemia. 
The presented in vivo results provide a 
proof-of-concept and encourage the development of a 
translationally more relevant administration of the 
drug and further tests on more complex disease 
models, such as animals with cardiovascular diseases. 
In addition, the combination of AmBleb with edema 
reducing therapies could have the potential to extend 
the efficiency of the treatment for ischemic stroke and 





hence improve the neurological outcomes [10, 11, 14, 
51-59, 65-68]. 
We established an unbiased method to assess the 
effects of MCAO and the dynamics of recovery in a 
large number of hypoxia-affected brain regions using 
published reference values of healthy rats. By using 
an independent reference set instead of comparing the 
ipsilesional and contralesional hemispheres, we were 
able to define the affected regions on both 
hemispheres after MCAO and found substantial 
improvement in the ipsilesional side of the AmBleb 
treated group. As previously shown, ischemia- 
induced hypoperfusion may affect certain brain 
regions differently based on the cerebral blood flow 
reduction, the degree of collateral circulation and the 
metabolic activity in human patients [69]. After 14 
days of the treatment we observed a tendency to 
relapse in both the rCBF values and hypoperfused 
brain volumes, which could possibly be due to the 
single administration of AmBleb and the additional 
effect of the permanent edema observed in the MRI 
images. In contrast, the relapse was not obvious in the 
neurological deficit scores. Moreover, several 
neurological features improved substantially when 
rCBF values were in the relapsing phase.  
We also showed that direct targeting of the 
effector molecule, SMM, has the same positive 
consequence but without the possible broad 
side-effect profile emerging from the inhibition of a 
central regulatory hub kinase, ROCK. The effects of 
the pharmacologically safe myosin-2 inhibitor, 
AmBleb indicate that SMM is a promising drug target 
candidate in ischemic stroke treatment. Thus, further 
studies are encouraged to assess the effect of myosin-2 
inhibition on regeneration after stroke involving fine 
sensorimotor and cognitive tests on older animals 
especially with comorbidities to more prudentially 
approach the human risk conditions according to the 
current consensus-based guidelines in stroke research 
[70]. 
Conclusion 
Direct targeting of SMM in precapillary SMCs 
and consequent opening of permanently blocked 
capillaries in the ischemic brain regions may fulfill 
both short- and long-term requirements towards an 
innovative medication. In addition, its combination 
with the current treatments has the potential to extend 
the treatment-eligibility criteria thereby allowing 
effective therapies to a broader population of stroke 
patients. 
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